Pluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming Leadership

SEATTLE, June 16, 2026 (GLOBE NEWSWIRE) -- Pluristyx, a leading provider of advanced induced pluripotent stem cell (iPSC) technologies and proprietary, genetically engineered solutions, today announced the Japanese Patent Office (JPO) issued a Notice of Allowance for Patent Application No. 2023-552219. The licensed patent, titled "Engineered Expression Constructs to Increase Protein Expression from Synthetic Ribonucleic Acid (RNA)" (nationalization of International Application No. PCT/US2022/017880), represents a critical expansion of Pluristyx's intellectual property portfolio. These unique synthetic mRNA constructs stabilize mRNA and increase protein expression without need for modified nucleosides, microRNA sites, or immune-evading factors. This allowance comes at a pivotal moment for regenerative medicine in Japan. A global leader in induced pluripotent stem cell (iPSC) research, Japan established an accelerated regulatory framework for iPSC-derived products in 2015. More than 11 years later, the first two landmark commercial iPSC-derived cell therapies have been approved. Pluristyx is addressing this critical industry bottleneck in the transition from R&D to commercial use by applying its unique synthetic mRNA technology to rapidly generate safe, clinical-grade iPSCs able to be manufactured at large commercial scale. By optimizing expression kinetics of synthetic RNA with a multiplex of key pluripotency transcription factors, the Pluristyx platform ... Full story available on Benzinga.com